- Markets
- Agriculture
- INDRANIB
INDRANIB
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Indrayani Biotech To Consider Issue Of Shares Via Rights Issue
Nov 11 (Reuters) - Indrayani Biotech Ltd INBT.BO:
INDRAYANI BIOTECH LTD - TO CONSIDER ISSUE OF SHARES VIA RIGHTS ISSUE
Source text: ID:nBSE7jR0yd
Further company coverage: INBT.BO
(([email protected];))
Nov 11 (Reuters) - Indrayani Biotech Ltd INBT.BO:
INDRAYANI BIOTECH LTD - TO CONSIDER ISSUE OF SHARES VIA RIGHTS ISSUE
Source text: ID:nBSE7jR0yd
Further company coverage: INBT.BO
(([email protected];))
Indrayani Biotech Says IBL Healthcare Disinvested 52,970 Equity Shares Of IHHC
Aug 29 (Reuters) - Indrayani Biotech Ltd INBT.BO:
IBL HEALTHCARE DISINVESTED 52,970 EQUITY SHARES OF IHHC
CONSIDERATION RECEIVED FROM SALE 5.3 MILLION RUPEES
Source text for Eikon: ID:nBSE9YG82v
Further company coverage: INBT.BO
(([email protected];))
Aug 29 (Reuters) - Indrayani Biotech Ltd INBT.BO:
IBL HEALTHCARE DISINVESTED 52,970 EQUITY SHARES OF IHHC
CONSIDERATION RECEIVED FROM SALE 5.3 MILLION RUPEES
Source text for Eikon: ID:nBSE9YG82v
Further company coverage: INBT.BO
(([email protected];))
Indrayani Biotech Says Unit IBL Healthcare Invested In Kniss Laboratories By Subscribing To Equity Shares Of Co
Aug 25 (Reuters) - Indrayani Biotech Ltd INBT.BO:
UNIT IBL HEALTHCARE INVESTED IN KNISS LABORATORIES BY SUBSCRIBING TO EQUITY SHARES OF CO
COST OF ACQUISITION 54.7 MILLION RUPEES
Source text for Eikon: ID:nBSEb4sN15
Further company coverage: INBT.BO
(([email protected];))
Aug 25 (Reuters) - Indrayani Biotech Ltd INBT.BO:
UNIT IBL HEALTHCARE INVESTED IN KNISS LABORATORIES BY SUBSCRIBING TO EQUITY SHARES OF CO
COST OF ACQUISITION 54.7 MILLION RUPEES
Source text for Eikon: ID:nBSEb4sN15
Further company coverage: INBT.BO
(([email protected];))
Indrayani Biotech Says Unit Intends To Acquire Controlling Stakes In M/S Peekay Mediequip
July 13 (Reuters) - Indrayani Biotech Ltd INBT.BO:
UNIT INTENDS TO ACQUIRE CONTROLLING STAKES IN M/S PEEKAY MEDIEQUIP
COST OF ACQUISITION AT 55.4 MILLION RUPEES AS FIRST TRANCHE
Source text for Eikon: ID:nBSE1ytKTJ
Further company coverage: INBT.BO
(([email protected];;))
July 13 (Reuters) - Indrayani Biotech Ltd INBT.BO:
UNIT INTENDS TO ACQUIRE CONTROLLING STAKES IN M/S PEEKAY MEDIEQUIP
COST OF ACQUISITION AT 55.4 MILLION RUPEES AS FIRST TRANCHE
Source text for Eikon: ID:nBSE1ytKTJ
Further company coverage: INBT.BO
(([email protected];;))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Indrayani Biotech do?
Indrayani Biotech, operating in the food sector, funds projects for cut flowers, strawberries, plantlets, and hybrid vegetable seeds. They distribute Hoechst India's hybrid seeds and aim to produce for them in the future.
Who are the competitors of Indrayani Biotech?
Indrayani Biotech major competitors are Trescon, Raghuvansh Agro, ABans Enterprises, Uma Expo, Riddhi Siddhi Gluco, State Trading Corp, Shree Oswal Seeds. Market Cap of Indrayani Biotech is ₹89 Crs. While the median market cap of its peers are ₹207 Crs.
Is Indrayani Biotech financially stable compared to its competitors?
Indrayani Biotech seems to be less financially stable compared to its competitors. Altman Z score of Indrayani Biotech is 1.7 and is ranked 6 out of its 8 competitors.
Does Indrayani Biotech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Indrayani Biotech latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Indrayani Biotech allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory, Short Term Loans & Advances
How strong is Indrayani Biotech balance sheet?
Indrayani Biotech balance sheet is weak and might have solvency issues
Is the profitablity of Indrayani Biotech improving?
The profit is oscillating. The profit of Indrayani Biotech is ₹7.15 Crs for TTM, ₹6.36 Crs for Mar 2024 and ₹8.74 Crs for Mar 2023.
Is the debt of Indrayani Biotech increasing or decreasing?
The debt of Indrayani Biotech is decreasing. Latest debt of Indrayani Biotech is ₹92.58 Crs as of Sep-24. This is less than Mar-24 when it was ₹107 Crs.
Is Indrayani Biotech stock expensive?
Indrayani Biotech is not expensive. Latest PE of Indrayani Biotech is 17.3, while 3 year average PE is 25.04. Also latest EV/EBITDA of Indrayani Biotech is 8.19 while 3yr average is 16.66.
Has the share price of Indrayani Biotech grown faster than its competition?
Indrayani Biotech has given lower returns compared to its competitors. Indrayani Biotech has grown at ~-14.26% over the last 3yrs while peers have grown at a median rate of 4.01%
Is the promoter bullish about Indrayani Biotech?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Indrayani Biotech is 33.28% and last quarter promoter holding is 33.28%.
Are mutual funds buying/selling Indrayani Biotech?
There is Insufficient data to gauge this.